CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Cardiopulmonary Exercise Testing: What Is its Value? Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial Transcatheter Mitral-Valve Repair in Patients with Heart Failure Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease Volume brings value Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

ConsensusNovember 2018

JOURNAL:J Am Coll Cardiol. Article Link

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Writing Committee, Sandeep RD, Brendan M et al. Keywords: ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus; Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D

FULL TEXT PDF